Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research
Maria R. Dauvermann, Graham Lee, Neil Dawson
British Journal of Pharmacology (2017) Vol. 174, Iss. 19, pp. 3136-3160
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Butyrate ameliorates quinolinic acid–induced cognitive decline in obesity models
Xing Ge, Mingxuan Zheng, Minmin Hu, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 4
Open Access | Times Cited: 48
Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
Holger Rosenbrock, Michael Desch, Glen Wunderlich
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1557-1566
Open Access | Times Cited: 44
Aging-induced tRNAGlu-derived fragment impairs glutamate biosynthesis by targeting mitochondrial translation-dependent cristae organization
Dingfeng Li, Xinyi Gao, Xiaolin Ma, et al.
Cell Metabolism (2024) Vol. 36, Iss. 5, pp. 1059-1075.e9
Closed Access | Times Cited: 20
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
W. Wolfgang Fleischhacker, Jana Podhorná, Martina Gröschl, et al.
The Lancet Psychiatry (2021) Vol. 8, Iss. 3, pp. 191-201
Closed Access | Times Cited: 101
Toxoplasmosis: A pathway to neuropsychiatric disorders
Shiraz Tyebji, Simona Seizova, Anthony J. Hannan, et al.
Neuroscience & Biobehavioral Reviews (2018) Vol. 96, pp. 72-92
Closed Access | Times Cited: 97
Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders
Pratik Chakraborty, Abhijit Dey, Abilash Valsala Gopalakrishnan, et al.
Ageing Research Reviews (2023) Vol. 85, pp. 101838-101838
Closed Access | Times Cited: 23
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 12
Chronic Pain–Related Cognitive Deficits: Preclinical Insights into Molecular, Cellular, and Circuit Mechanisms
Siyi Han, Jie Wang, Wen Zhang, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 10, pp. 8123-8143
Closed Access | Times Cited: 8
Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling
Yayan Luo, Yu Yang, Min-Ling Zhang, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 9, pp. 4702-4718
Closed Access | Times Cited: 41
Neurochemistry of Visual Attention
Denise Lockhofen, Christoph Mulert
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 33
Evaluating the Impact of Adding Lee Silverman Voice Treatment BIG into Routine Physiotherapy on Both Motor and Nonmotor Functions in Individuals with Parkinson’s Disease
Zahra Sadaghiani, Nahid Tahan, Soheila Ganjeh, et al.
Dubai Medical Journal (2025) Vol. 8, Iss. 1, pp. 12-22
Open Access
The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia
Gislaine Z. Réus, Indianara R. T. Becker, Giselli Scaini, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017) Vol. 81, pp. 55-63
Closed Access | Times Cited: 45
Glutamate and functional connectivity - support for the excitatory-inhibitory imbalance hypothesis in autism spectrum disorders
J E Siegel, Liana Romaniuk, Heather C. Whalley, et al.
Psychiatry Research Neuroimaging (2021) Vol. 313, pp. 111302-111302
Closed Access | Times Cited: 29
mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia
Cláudia Régio Brambilla, Tanja Veselinović, Ravichandran Rajkumar, et al.
Human Brain Mapping (2020) Vol. 41, Iss. 10, pp. 2762-2781
Open Access | Times Cited: 31
Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case–control study at 7 T
Beata R. Godlewska, Amedeo Minichino, Uzay E. Emir, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 23
Effects of the Glycine Transporter-1 Inhibitor Iclepertin (BI 425809) on Sensory Processing, Neural Network Function, and Cognition in Animal Models Related to Schizophrenia
Holger Rosenbrock, Cornelia Dorner‐Ciossek, Riccardo Giovannini, et al.
Journal of Pharmacology and Experimental Therapeutics (2022) Vol. 382, Iss. 2, pp. 223-232
Open Access | Times Cited: 17
Novel α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor (AMPAR) potentiator LT‐102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia
Xueyu Qi, Xueli Yu, Wei Long, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 4
Open Access | Times Cited: 3
Enhanced Novel Object Recognition and Spatial Memory in Rats Selectively Bred for High Nicotine Preference
Eren Bekci, Ramazan Can Gokmen, Lütfiye Kanıt, et al.
Brain Sciences (2024) Vol. 14, Iss. 5, pp. 427-427
Open Access | Times Cited: 3
Beating pain with psychedelics: Matter over mind?
Igor Elman, Amanda C. Pustilnik, David Borsook
Neuroscience & Biobehavioral Reviews (2021) Vol. 134, pp. 104482-104482
Closed Access | Times Cited: 21
Stress-Induced Neurodegeneration: The Potential for Coping as Neuroprotective Therapy
Shelby A. Kline, Michael S. Mega
American Journal of Alzheimer s Disease & Other Dementias® (2020) Vol. 35
Open Access | Times Cited: 23
Effect of Neonatal Treatment With the NMDA Receptor Antagonist, MK-801, During Different Temporal Windows of Postnatal Period in Adult Prefrontal Cortical and Hippocampal Function
Maria Plataki, Konstantinos Diskos, Christos Sougklakos, et al.
Frontiers in Behavioral Neuroscience (2021) Vol. 15
Open Access | Times Cited: 18
Fat loss and muscle gain: The possible role of cortical glutamate in determining the efficacy of physical exercise
Muhammad Abdullah, Shih‐Hsien Lin, Li-Chung Huang, et al.
Obesity Research & Clinical Practice (2024) Vol. 18, Iss. 3, pp. 163-170
Closed Access | Times Cited: 2
Attenuation Effects of Alpha-Pinene Inhalation on Mice with Dizocilpine-Induced Psychiatric-Like Behaviour
Hiroshi Ueno, Atsumi Shimada, Shunsuke Suemitsu, et al.
Evidence-based Complementary and Alternative Medicine (2019) Vol. 2019, pp. 1-12
Open Access | Times Cited: 22
NMDA Receptor Antagonist Effects on Speech-Related Mismatch Negativity and Its Underlying Oscillatory and Source Activity in Healthy Humans
Sara de la Salle, Dhrasti Shah, Joëlle Choueiry, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 21
Neurobiological substrates of persistent working memory deficits and cocaine-seeking in the prelimbic cortex of rats with a history of extended access to cocaine self-administration
Christina Gobin, John Shallcross, Marek Schwendt
Neurobiology of Learning and Memory (2019) Vol. 161, pp. 92-105
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top